Cargando...
Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN(®))
PURPOSE: There are limited published data regarding the use of supplemental intravitreal therapies in patients with diabetic macular edema (DME) following treatment with the 0.19 mg fluocinolone acetonide (FAc; ILUVIEN(®)) intravitreal implant. The aim of this report was to analyze five challenging...
Gardado en:
| Publicado en: | Int Med Case Rep J |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7501957/ https://ncbi.nlm.nih.gov/pubmed/32982484 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IMCRJ.S262587 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|